Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Capital Raise

Disc Medicine Shares Jump 10% in 4 Days Since $450 Million Public Offering

Disc Medicine Secures $450 Million Public Offering to Extend Cash Runway into 2030

+10.13% in 4 days $75.03 when we broke this story → $82.63 at 3:10 PM ET, 28 Oct 2026

Disc Medicine (NASDAQ: IRON) has successfully closed an upsized underwritten public offering of 6,000,000 shares of common stock at $75.00 per share, raising $450 million in gross proceeds. This capital infusion is designed to support the clinical advancement of its hematology pipeline and extends the company's operational runway through the end of the decade.

Analysis, biochemistry, biologist, biology. Stock photo illustrating Disc Medicine's capital raise story.
Disc Medicine, Inc. · Healthcare · Photo: Kost9n4 / Pixabay
Key numbers
Deal value$450M
Share of market cap15.6%

Key highlights

  • Issued 6,000,000 common shares at a fixed price of $75.00 per share
  • Underwriters granted a 30-day option for an additional 900,000 shares
  • Net proceeds estimated at $422.4 million after standard transaction costs
  • Projected cash runway extended to 2030 for operations and debt service
  • Preliminary Q3 2026 cash and equivalents reported at $682.8 million

What Is the Capital Raise?

Disc Medicine completed an upsized underwritten public offering of 6,000,000 common shares priced at $75.00 each, generating $450 million in gross proceeds. The offering officially closed on October 22, 2026, with Jefferies, Leerink Partners, Morgan Stanley, and Cantor acting as joint book-running managers. Beyond the primary issuance, the company granted underwriters a 30-day option to acquire an additional 900,000 shares at the same public offering price. This transaction significantly strengthens the balance sheet, following a preliminary cash report of $682.8 million as of September 30, 2026, ensuring high liquidity for upcoming clinical programs.

Use of Proceeds

  • Funding research and clinical development of the current hematology pipeline
  • Supporting the potential commercialization of bitopertin for EPP and XLP
  • Advancing pre-commercialization activities for additional product candidates
  • Financing debt service obligations and general working capital requirements

Strategic Rationale

The timing of this capital raise aligns with critical regulatory milestones, including the targeted resubmission of the New Drug Application for bitopertin by year-end 2026. By securing this capital now, Disc Medicine extends its operational runway into 2030, effectively de-risking the financial path through potential FDA approval and market launch. This long-term funding strategy reduces the immediate need for dilutive financing during the mid-stage commercialization phase. The extension into the next decade ensures that the company can maintain momentum across its broader portfolio without relying on immediate cash inflows from marketed products.

Business Overview

Based in Watertown, Massachusetts, Disc Medicine is a clinical-stage biopharmaceutical firm focused on the discovery and commercialization of treatments for serious hematologic diseases. Its primary focus involves targeting fundamental biological pathways, such as heme synthesis and iron metabolism. The flagship candidate, bitopertin, is being developed for erythropoietic protoporphyria, a rare condition characterized by intense photosensitivity. The company's pipeline also includes programs aimed at addressing other erythroid and iron-related disorders, leveraging a diverse set of therapeutic mechanisms to address significant unmet needs in the global hematology sector.

Financial Context

Disc Medicine has maintained an active financing profile, including a 250 million dollar offering in October 2025 and a 225.5 million dollar raise in January 2025. This latest 450 million dollar transaction marks a significant step up in scale, nearly doubling the size of previous rounds. Prior to this offering, the company reported 718 million dollars in cash and equivalents as of June 30, 2026, with a runway that previously extended into 2029. The inclusion of these new proceeds, alongside existing credit facilities, provides one of the most substantial cash cushions among clinical-stage biotechnology peers.

Disc Medicine, Inc. share price · last month
Line chart of Disc Medicine, Inc.'s share price over the last month, from $78.93 on 19 Oct → $76.59 on 16 Nov; our story on 22 Oct at $75.03.

Up 2.1% since our story on 22 Oct: $75.03 when we broke it → $76.59 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$78.93
20 Oct$79.48
21 Oct$76.00
22 Oct$75.03
23 Oct$74.51
26 Oct$77.66
27 Oct$79.90
28 Oct$83.20
29 Oct$82.84
30 Oct$80.84
2 Nov$78.62
3 Nov$81.16
4 Nov$83.28
5 Nov$78.47
6 Nov$78.91
9 Nov$81.26
10 Nov$84.64
11 Nov$87.08
12 Nov$83.23
13 Nov$80.00
16 Nov$76.59
Earlier announcements by Disc Medicine, Inc.
DateAnnouncementAmount
20 Oct 2026Pricing of upsized public offering of common stockSource: ir.discmedicine.com$450.0 Million
25 Jun 2026First amendment to loan agreement and term loan drawdownSource: SEC filing$30.0 Million
21 Oct 2025Pricing of upsized public offering of common stock and pre-funded warrantsSource: ir.discmedicine.com$250.0 Million
22 Jan 2025Pricing of upsized public offering of common stock and pre-funded warrantsSource: ir.discmedicine.com$225.5 Million
15 Nov 2024Controlled equity offering sales agreement (at-the-market equity offering program)Source: ir.discmedicine.com$200.0 Million
06 Nov 2024Loan and security agreement for senior secured term loan facilitySource: ir.discmedicine.com$200.0 Million
Disc Medicine, Inc. · financial snapshot
Share price$75.03
Market cap$2.9B
1-month price change+9.56%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Disc Medicine, Inc. announcing the closing of a $450 million underwritten public offering.

Read the filing ↗
All Disc Medicine, Inc. filings and newsView all →

Track Disc Medicine, Inc. live

Get the next Disc Medicine, Inc. SEC filing seconds after it lands.

More from Disc Medicine, Inc.

All →

More in Capital Raise

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.